IDP 023
Alternative Names: IDP-023Latest Information Update: 29 May 2024
At a glance
- Originator Indapta Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
- Preclinical Solid tumours
Most Recent Events
- 23 May 2024 Indapta Therapeutics announces their intention to submit an IND application with the US FDA for Multiple sclerosis
- 23 May 2024 Indapta Therapeutics plans a phase I trial for Multiple sclerosis in 2024
- 29 Feb 2024 IDP 023 receives Fast track status from the US FDA for Non-Hodgkin’s lymphoma and Myeloma